top of page


Merck KGaA agrees $1.3 billion acquisition of Silence Therapeutics to expand rare disease siRNA pipeline
Merck KGaA has agreed to acquire Silence Therapeutics in an all-cash transaction valued at approximately $1.3 billion in equity, expanding its RNA interference pipeline.

nuaxia
Oct 202 min read


Roche licenses Rona Therapeutics ALK7-targeting RNAi obesity therapy in deal worth up to $1.16 billion
Roche has secured worldwide rights to Rona Therapeutics' investigational ALK7-targeting RNAi therapy in an obesity and metabolic disease licensing agreement worth up to $1.16 billion.

nuaxia
Oct 152 min read


Alnylam and Inceptive Launch $2B AI Partnership to Accelerate RNAi Drug Discovery
Alnylam Pharmaceuticals has entered a collaboration worth up to $2bn with Inceptive Nucleics, combining RNA interference (RNAi) drug development expertise with generative AI models specifically designed for sequence-based medicines.

nuaxia
Jun 53 min read
bottom of page